Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Average Rating of "Buy" from Analysts

Key Points

• Compass Therapeutics, Inc. has received an average recommendation of "Buy" from ten analysts, with a 12-month price target of approximately $12.89 per share.
• Several brokers, including Raymond James and Guggenheim, have recently issued positive reports, with price targets ranging from $9.00 to $32.00.
• 68.43% of Compass Therapeutics' stock is currently owned by institutional investors, indicating strong institutional interest in the company.

Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) have been given an average recommendation of "Buy" by the ten research firms that are covering the firm, MarketBeat reports. Nine investment analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $12.8889.

Several brokerages have recently weighed in on CMPX. Guggenheim increased their price target on Compass Therapeutics from $10.00 to $12.00 and gave the stock a "buy" rating in a report on Tuesday, August 12th. Raymond James Financial upgraded Compass Therapeutics to an "outperform" rating and set a $9.00 price target on the stock in a report on Tuesday, July 1st. Finally, D. Boral Capital reiterated a "buy" rating and issued a $32.00 price target on shares of Compass Therapeutics in a report on Tuesday, August 12th.

Compass Therapeutics Stock Performance

CMPX stock traded down $0.06 during midday trading on Friday, reaching $3.37. 142,254 shares of the company traded hands, compared to its average volume of 1,392,578. Compass Therapeutics has a 52-week low of $1.27 and a 52-week high of $4.08. The business has a 50 day moving average of $2.97 and a 200-day moving average of $2.47. The firm has a market capitalization of $466.56 million, a price-to-earnings ratio of -7.50 and a beta of 1.50.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.01). Research analysts anticipate that Compass Therapeutics will post -0.36 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of CMPX. Marex Group plc bought a new stake in Compass Therapeutics during the 2nd quarter valued at $61,000. Adage Capital Partners GP L.L.C. lifted its position in Compass Therapeutics by 11.3% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 4,424,868 shares of the company's stock worth $11,505,000 after acquiring an additional 449,868 shares during the period. Vivo Capital LLC raised its stake in shares of Compass Therapeutics by 70.0% during the 2nd quarter. Vivo Capital LLC now owns 6,043,466 shares of the company's stock valued at $15,713,000 after buying an additional 2,487,443 shares during the last quarter. Invesco Ltd. raised its stake in shares of Compass Therapeutics by 58.1% during the 2nd quarter. Invesco Ltd. now owns 58,735 shares of the company's stock valued at $153,000 after buying an additional 21,578 shares during the last quarter. Finally, XTX Topco Ltd purchased a new position in shares of Compass Therapeutics during the 2nd quarter valued at about $84,000. 68.43% of the stock is currently owned by hedge funds and other institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.